Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Protein electrophoresis and immunoglobulin analysis in HIV-infected patients.

Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA.

Am J Clin Pathol. 2007 Oct;128(4):596-603.

2.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

3.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
4.

Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.

El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B; Swiss HIV Cohort Study.

AIDS. 2008 May 31;22(9):1019-28. doi: 10.1097/QAD.0b013e3282fc9c03.

PMID:
18520345
5.

Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.

Reiche EM, Bonametti AM, Morimoto HK, Morimoto AA, Wiechemann SL, Matsuo T, Vissoci Reiche F, Vogler IH.

Int J Mol Med. 2008 Mar;21(3):387-95.

PMID:
18288387
6.

Prevalence of HIV-associated ophthalmic disease among patients enrolling for antiretroviral treatment in India: a cross-sectional study.

Pathai S, Deshpande A, Gilbert C, Lawn SD.

BMC Infect Dis. 2009 Sep 23;9:158. doi: 10.1186/1471-2334-9-158.

7.

Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.

Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, Musset L; ALT ANRS CO15 Study Group.

Clin Infect Dis. 2009 Jan 1;48(1):123-32. doi: 10.1086/595013.

8.

Elevated levels of vitamin B12 and folate in vertically infected children with HIV-1.

Malik ZA, Abadi J, Sansary J, Rosenberg M.

AIDS. 2009 Jan 28;23(3):403-7. doi: 10.1097/QAD.0b013e32831ef4f7.

PMID:
19114857
9.

The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.

Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E.

Biomed Pharmacother. 2009 Sep;63(8):561-5. doi: 10.1016/j.biopha.2008.09.015. Epub 2008 Nov 5.

PMID:
19026516
10.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
11.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
12.

[Efficacy of vaccination against hepatitis B in adult with HIV infection].

Kalinowska-Nowak A, Bociaga-Jasik M, Garlicki A, Mach T.

Przegl Epidemiol. 2007;61(2):339-47. Polish.

PMID:
17956052
13.

Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.

Antivir Ther. 2009;14(3):339-47.

PMID:
19474468
14.

Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.

Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.

HIV Med. 2008 May;9(5):300-6. doi: 10.1111/j.1468-1293.2008.00564.x.

15.

Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.

Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, de Quiros JC, Conde MS, Muñoz-Fernández MA, Resino S.

J Infect. 2008 Feb;56(2):130-6. doi: 10.1016/j.jinf.2007.12.001. Epub 2008 Jan 14.

PMID:
18192020
16.

Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.

Anderson AM, Kosinski AS, Bartlett JA.

Antivir Ther. 2007;12(7):1041-8.

PMID:
18018762
17.

Audiologic and vestibular findings in a sample of human immunodeficiency virus type-1-infected Mexican children under highly active antiretroviral therapy.

Palacios GC, Montalvo MS, Fraire MI, Leon E, Alvarez MT, Solorzano F.

Int J Pediatr Otorhinolaryngol. 2008 Nov;72(11):1671-81. doi: 10.1016/j.ijporl.2008.08.002. Epub 2008 Sep 23.

PMID:
18814921
18.

Brazilian HIV-infected population: assessment of the needs of endodontic treatment in the post-highly active antiretroviral therapy era.

de Brito LC, da Rosa MA, Lopes VS, e Ferreira EF, Vieira LQ, Sobrinho AP.

J Endod. 2009 Sep;35(9):1178-81. doi: 10.1016/j.joen.2009.05.004. Epub 2009 Jun 28.

PMID:
19720212
19.

Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.

Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Souala MF, Costagliola D; French Hospital Database on HIV ANRS CO4.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):422-6. doi: 10.1097/QAI.0b013e3181ab6ec1.

PMID:
19521249
20.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
Items per page

Supplemental Content

Write to the Help Desk